Advertisement

Dyslipidemias pp 251-266 | Cite as

Genetic Abetalipoproteinaemia and Hypobetalipoproteinaemia

  • Amanda J. Hooper
  • John R. BurnettEmail author
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

The monogenic hypocholesterolaemic lipid disorders are classified depending on the lipid biochemical phenotype, gene involved, and mode of inheritance of the condition, together with the severity of the mutation or mutations present. These disorders may or may not be associated with clinical manifestations such as fat malabsorption, growth failure, fat-soluble vitamin deficiency, fatty liver disease, and neuro-ophthalmological dysfunction. We have reviewed the molecular basis, pathogenesis, and clinical aspects of these disorders of apolipoprotein (apo) B production and catabolism, focusing on abetalipoproteinaemia, familial hypobetalipoproteinaemia, and chylomicron retention disease.

Keywords

Abetalipoproteinaemia Apolipoprotein B Cholesterol Chylomicron retention disease Familial hypobetalipoproteinaemia Genetics Hypobetalipoproteinaemia Hypocholesterolaemia Low-density lipoprotein Microsomal triglyceride transfer protein Molecular mechanisms Regulation Triglyceride Very low-density lipoprotein 

Notes

Acknowledgements

This work was supported by the National Health and Medical Research Council Project Grant 1010133 (to AJH and JRB) and a Practitioner Fellowship from the Royal Perth Hospital Medical Research Foundation (to JRB).

References

  1. 1.
    Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci. 2005;42(5):515–45.CrossRefPubMedGoogle Scholar
  2. 2.
    Hooper AJ, Burnett JR. Update on primary hypobetalipoproteinaemia.Curr Atheroscler Rep2014;16(7):423.Google Scholar
  3. 3.
    Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: abetalipoproteinaemia - Update 2014. Eur J Hum Genet. 2014 Oct 22. doi:10.1038/ ejhg.2014.224.Google Scholar
  4. 4.
    Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: familial hypobetalipoproteinaemia (APOB). Eur J Hum Genet. 2012;20(8). doi:10.1038/ejhg.2012.85.Google Scholar
  5. 5.
    Peretti N, Sassolas A, Roy CC, Deslandres C, Charcosset M, Castagnetti J, et al. Guidelines for the diagnosis and management of chylomicron retention disease based on a review of the literature and the experience of two centers. Orphanet J Rare Dis. 2010;5:24.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Hooper AJ, Burnett JR. Recent developments in the genetics of LDL deficiency. Curr Opin Lipidol. 2013;24(2):111–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220–7.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Bassen FA, Kornzweig AL. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood. 1950;5(4):381–7.PubMedGoogle Scholar
  10. 10.
    Sturman RM. The Bassen-Kornzweig syndrome: 18 years in evolution. J Mt Sinai Hosp N Y. 1968;35(5):489–517.PubMedGoogle Scholar
  11. 11.
    Wolff JA, Bauman WA. Studies concerning acanthocytosis: a new genetic syndrome with absent beta lipoprotein. Am J Dis Child. 1961;102:478.Google Scholar
  12. 12.
    Young SG, Bertics SJ, Curtiss LK, Witztum JL. Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest. 1987;79(6):1831–41.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Young SG, Northey ST, McCarthy BJ. Low plasma cholesterol levels caused by a short deletion in the apolipoprotein B gene. Science. 1988;241(4865):591–3.CrossRefPubMedGoogle Scholar
  14. 14.
    Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258(5084):999–1001.CrossRefPubMedGoogle Scholar
  15. 15.
    Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365(6441):65–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Shoulders CC, Brett DJ, Bayliss JD, Narcisi TM, Jarmuz A, Grantham TT, et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet. 1993;2(12):2109–16.CrossRefPubMedGoogle Scholar
  17. 17.
    Anderson CM, Townley RR, Freemanm, Johansen P. Unusual causes of steatorrhoea in infancy and childhood. Med J Aust. 1961;48(2):617–22.PubMedGoogle Scholar
  18. 18.
    Bouma ME, Beucler I, Aggerbeck LP, Infante R, Schmitz J. Hypobetalipoproteinemia with accumulation of an apoprotein B-like protein in intestinal cells. Immunoenzymatic and biochemical characterization of seven cases of Anderson’s disease. J Clin Invest. 1986;78(2):398–410.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Pessah M, Benlian P, Beucler I, Loux N, Schmitz J, Junien C, et al. Anderson’s disease: genetic exclusion of the apolipoprotein-B gene in two families. J Clin Invest. 1991;87(1):367–70.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Jones B, Jones EL, Bonney SA, Patel HN, Mensenkamp AR, Eichenbaum-Voline S, et al. Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat Genet. 2003;34(1):29–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PW, Schaefer EJ. Frequency of apoB and apoE gene mutations as causes of hypobetalipoproteinemia in the Framingham offspring population. Arterioscler Thromb Vasc Biol. 1998;18(11):1745–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37(2):161–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193(2):445–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Hussain MM, Shi J, Dreizen P. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res. 2003;44(1):22–32.CrossRefPubMedGoogle Scholar
  25. 25.
    Pariyarath R, Wang H, Aitchison JD, Ginsberg HN, Welch WJ, Johnson AE, et al. Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome. J Biol Chem. 2001;276(1):541–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Ohashi K, Ishibashi S, Osuga J, Tozawa R, Harada K, Yahagi N, et al. Novel mutations in the microsomal triglyceride transfer protein gene causing abetalipoproteinemia. J Lipid Res. 2000;41(8):1199–204.PubMedGoogle Scholar
  27. 27.
    Rehberg EF, Samson-Bouma ME, Kienzle B, Blinderman L, Jamil H, Wetterau JR, et al. A novel abetalipoproteinemia genotype. Identification of a missense mutation in the 97-kDa subunit of the microsomal triglyceride transfer protein that prevents complex formation with protein disulfide isomerase. J Biol Chem. 1996;271(47):29945–52.CrossRefPubMedGoogle Scholar
  28. 28.
    Wang J, Hegele RA. Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. Hum Mutat. 2000;15(3):294–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Miller SA, Burnett JR, Leonis MA, McKnight CJ, van Bockxmeer FM, Hooper AJ. Novel missense MTTP gene mutations causing abetalipoproteinaemia. Biochim Biophys Acta 2014;1842(10):1548–54.Google Scholar
  30. 30.
    Linton MF, Farese RV, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993;34(4):521–41.PubMedGoogle Scholar
  31. 31.
    Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci. 2005;62(12):1372–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem. 2011;54:81–107.CrossRefPubMedGoogle Scholar
  33. 33.
    Burnett JR, Shan J, Miskie BA, Whitfield AJ, Yuan J, Tran K, et al. A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia. J Biol Chem. 2003;278(15):13442–52.CrossRefPubMedGoogle Scholar
  34. 34.
    Burnett JR, Zhong S, Jiang ZG, Hooper AJ, Fisher EA, McLeod RS, et al. Missense mutations in APOB within the betaalpha1 domain of human APOB-100 result in impaired secretion of apoB and apoB-containing lipoproteins in familial hypobetalipoproteinemia. J Biol Chem. 2007;282(33):24270–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhong S, Magnolo AL, Sundaram M, Zhou H, Yao EF, Leo ED, et al. Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia—evidence for feedback inhibition of lipogenesis and post-endoplasmic reticulum degradation of apolipoprotein B. J Biol Chem. 2010;285(9):6453–64.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001;276(12):9214–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and apoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 1999;19(11):2714–21.CrossRefPubMedGoogle Scholar
  38. 38.
    Parhofer KG, Barrett PHR, Aguilar-Salinas CA, Schonfeld G. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: in vivo studies in human apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J Lipid Res. 1996;37(4):844–52.PubMedGoogle Scholar
  39. 39.
    Yao Z, McLeod RS. Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins. Biochim Biophys Acta. 1994;1212(2):152–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Yao ZM, Blackhart BD, Linton MF, Taylor SM, Young SG, McCarthy BJ. Expression of carboxyl-terminally truncated forms of human apolipoprotein B in rat hepatoma cells. Evidence that the length of apolipoprotein B has a major effect on the buoyant density of the secreted lipoproteins. J Biol Chem. 1991;266(5):3300–8.PubMedGoogle Scholar
  41. 41.
    Parhofer KG, Barrett PHR, Bier DM, Schonfeld G. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo. J Clin Invest. 1992;89(6):1931–7.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Sherva R, Yue P, Schonfeld G, Neuman RJ. Evidence for a quantitative trait locus affecting low levels of apolipoprotein B and low density lipoprotein on chromosome 10 in Caucasian families. J Lipid Res. 2007;48(12):2632–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Yuan B, Neuman R, Duan SH, Weber JL, Kwok PY, Saccone NL, et al. Linkage of a gene for familial hypobetalipoproteinemia to chromosome 3p21.1–22. Am J Hum Genet. 2000;66(5):1699–704.CrossRefPubMedCentralPubMedGoogle Scholar
  44. 44.
    Siddiqi SA, Gorelick FS, Mahan JT, Mansbach CM 2nd. COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J Cell Sci. 2003;116(Pt 2):415–27.CrossRefPubMedGoogle Scholar
  45. 45.
    Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53(12):2515–24.CrossRefPubMedCentralPubMedGoogle Scholar
  46. 46.
    Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6.CrossRefPubMedGoogle Scholar
  47. 47.
    Shimamura M, Matsuda M, Yasumo H, Okazaki M, Fujimoto K, Kono K, et al. Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27(2):366–72.CrossRefPubMedGoogle Scholar
  48. 48.
    Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284(3):1419–24.CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Nakajima K, Kobayashi J, Mabuchi H, Nakano T, Tokita Y, Nagamine T, et al. Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma. Ann Clin Biochem. 2010;47(Pt 5):423–31.CrossRefPubMedGoogle Scholar
  50. 50.
    Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M, Wetterau JR. The role of the microsomal triglyceride transfer protein in abetalipoproteinemia. Annu Rev Nutr. 2000;20:663–97.CrossRefPubMedGoogle Scholar
  51. 51.
    Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, et al., editors. The metabolic and molecular bases of inherited disease. 8th edn. New York: McGraw-Hill; 2001. pp. 2717–52.Google Scholar
  52. 52.
    Delpre G, Kadish U, Glantz I, Avidor I. Endoscopic assessment in abetalipoproteinemia (Bassen-Kornzweig-syndrome). Endoscopy. 1978;10(1):59–62.CrossRefPubMedGoogle Scholar
  53. 53.
    Kayden HJ, Bessis M. Morphology of normal erythrocyte and acanthocyte using Nomarski optics and the scanning electron microscope. Blood. 1970;35(4):427–36.PubMedGoogle Scholar
  54. 54.
    Mier M, Schwartz SO, Boshes B. Acanthrocytosis, pigmentary degeneration of the retina and ataxic neuropathy: a genetically determined syndrome and associated metabolic disorder. Blood. 1960;16:1586–608.PubMedGoogle Scholar
  55. 55.
    Caballero FM, Buchanan GR. Abetalipoproteinemia presenting as severe vitamin K deficiency. Pediatrics. 1980;65(1):161–3.PubMedGoogle Scholar
  56. 56.
    Di Filippo M, Moulin P, Roy P, Samson-Bouma ME, Collardeau-Frachon S, Chebel-Dumont S, et al. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolaemia. J Hepatol 2014;61(4):891–902.Google Scholar
  57. 57.
    Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology. 1974;67(1):107–18.PubMedGoogle Scholar
  58. 58.
    Tanyel MC, Mancano LD. Neurologic findings in vitamin E deficiency. Am Fam Physician. 1997;55(1):197–201.PubMedGoogle Scholar
  59. 59.
    Cogan DG, Rodrigues M, Chu FC, Schaefer EJ. Ocular abnormalities in abetalipoproteinemia. A clinicopathologic correlation. Ophthalmology. 1984;91(8):991–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Ogata H, Akagi K, Baba M, Nagamatsu A, Suzuki N, Nomiyama K, et al. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol. 1997;92(2):339–42.PubMedGoogle Scholar
  61. 61.
    Schonfeld G, Patterson BW, Yablonskiy DA, Tanoli TS, Averna M, Elias N, et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res. 2003;44(3):470–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res. 2003;44(5):878–83.CrossRefPubMedGoogle Scholar
  63. 63.
    Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med. 1976;88(6):941–57.PubMedGoogle Scholar
  64. 64.
    Sankatsing RR, Fouchier SW, de Haan S, Hutten BA, de Groot E, Kastelein JJ, et al. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005;25:1979–84.CrossRefPubMedGoogle Scholar
  65. 65.
    Peretti N, Roy CC, Sassolas A, Deslandres C, Drouin E, Rasquin A, et al. Chylomicron retention disease: a long term study of two cohorts. Mol Genet Metab. 2009;97(2):136–42.CrossRefPubMedGoogle Scholar
  66. 66.
    Narcisi TM, Shoulders CC, Chester SA, Read J, Brett DJ, Harrison GB, et al. Mutations of the microsomal triglyceride-transfer-protein gene in abetalipoproteinemia. Am J Hum Genet. 1995;57(6):1298–310.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Ouguerram K, Zair Y, Kasbi-Chadli F, Nazih H, Bligny D, Schmitz J, et al. Low rate of production of apolipoproteins B100 and AI in 2 patients with Anderson disease (chylomicron retention disease). Arterioscler Thromb Vasc Biol. 2012;32(6):1520–5.CrossRefPubMedGoogle Scholar
  68. 68.
    Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, et al. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007;195(2):e19–27.CrossRefPubMedGoogle Scholar
  69. 69.
    Johansen CT, Dubé JB, Loyzer MN, MacDonald A, Carter DE, McIntyre AD, et al. LipidSeq: a nextgeneration clinical resequencing panel for monogenic dyslipidemias. J Lipid Res. 2014;55(4):765–72.Google Scholar
  70. 70.
    De Biase SG, Fernandes SF, Gianini RJ, Duarte JL. Vegetarian diet and cholesterol and triglycerides levels. Arq Bras Cardiol. 2007;88(1):35–9.CrossRefPubMedGoogle Scholar
  71. 71.
    Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis. 2008;3:19.CrossRefPubMedCentralPubMedGoogle Scholar
  72. 72.
    Chowers I, Banin E, Merin S, Cooper M, Granot E. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye. 2001;15(Pt 4):525–30.CrossRefPubMedGoogle Scholar
  73. 73.
    Muller DP, Lloyd JK. Effect of large oral doses of vitamin E on the neurological sequelae of patients with abetalipoproteinemia. Ann N Y Acad Sci. 1982;393:133–44.CrossRefPubMedGoogle Scholar
  74. 74.
    Muller DP, Lloyd JK, Wolff OH. The role of vitamin E in the treatment of the neurological features of abetalipoproteinaemia and other disorders of fat absorption. J Inherit Metab Dis. 1985;8(Suppl 1):88–92.CrossRefPubMedGoogle Scholar
  75. 75.
    Runge P, Muller DP, McAllister J, Calver D, Lloyd JK, Taylor D. Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinaemia. Brit J Ophthalmol. 1986;70(3):166–73.CrossRefGoogle Scholar
  76. 76.
    Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004;45(5):941–7.CrossRefPubMedGoogle Scholar
  77. 77.
    Tarugi P, Lonardo A, Ballarini G, Erspamer L, Tondelli E, Bertolini S, et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol. 2000;33(3):361–70.CrossRefPubMedGoogle Scholar
  78. 78.
    Whitfield AJ, Barrett PHR, Robertson K, Havlat MF, van Bockxmeer FM, Burnett JR. Liver dysfunction and steatosis in familial hypobetalipoproteinemia. Clin Chem. 2005;51(1):266–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Visser ME, Lammers NM, Nederveen AJ, van der Graaf M, Heerschap A, Ackermans MT, et al. Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia. Diabetologia. 2011;54(8):2113–21.CrossRefPubMedCentralPubMedGoogle Scholar
  80. 80.
    Hooper AJ, Adams LA, Burnett JR. Genetic determinants of hepatic steatosis in man. J Lipid Res. 2011;52(4):593–617.CrossRefPubMedCentralPubMedGoogle Scholar
  81. 81.
    Lonardo A, Tarugi P, Ballarini G, Bagni A. Familial heterozygous hypobetalipoproteinemia, extrahepatic primary malignancy, and hepatocellular carcinoma. Dig Dis Sci. 1998;43(11):2489–92.CrossRefPubMedGoogle Scholar
  82. 82.
    Welty FK. Hypobetalipoproteinaemia and abetalipoproteinaemia.Curr Opin Lipidol 2014;25(3):161–8.Google Scholar
  83. 83.
    Muller DP. Vitamin E and neurological function. Mol Nutr Food Res. 2010;54(5):710–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Kayden HJ, Hatam LJ, Traber MG. The measurement of nanograms of tocopherol from needle aspiration biopsies of adipose tissue: normal and abetalipoproteinemic subjects. J Lipid Res. 1983;24(5):652–6.PubMedGoogle Scholar
  85. 85.
    Clarke MW, Hooper AJ, Headlam HA, Wu JH, Croft KD, Burnett JR. Assessment of tocopherol metabolism and oxidative stress in familial hypobetalipoproteinemia. Clin Chem. 2006;52(7):1339–45.CrossRefPubMedGoogle Scholar
  86. 86.
    Vongsuvanh R, Hooper AJ, Coakley JC, Macdessi JS, O’Loughlin EV, Burnett JR, et al. Novel mutations in abetalipoproteinaemia and homozygous familial hypobetalipoproteinaemia. J Inherit Metab Dis. 2007;30(6):990.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press 2015

Authors and Affiliations

  1. 1.Department of Clinical Biochemistry, PathWest Laboratory Medicine WARoyal Perth HospitalPerthAustralia
  2. 2.School of Medicine & PharmacologyUniversity of Western AustraliaPerthAustralia
  3. 3.Schools of Medicine & Pharmacology and Pathology & Laboratory MedicineUniversity of Western AustraliaPerthAustralia

Personalised recommendations